LVivo IQS vs Lung AI

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 70/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

LVivo IQS

by DiA Imaging Analysis

Lung AI

by Multiple (e.g., RevealDx, Optellum, LungLife AI, Qure.ai, Arterys, DeepHealth, HeartLung.AI)

AI Verdict

Tool A (LVivo IQS) is a vendor-neutral AI software solution specializing in detailed cardiac function analysis and broader ultrasound image interpretation. Tool B (Lung AI) is integrated with a proprietary handheld ultrasound device, offering AI for both lung pathology detection and general cardiac indicators. While both leverage AI for ultrasound in cardiology and emergency medicine, their primary focus areas and deployment models offer distinct advantages for different clinical needs.

Choose LVivo IQS if…

Choose LVivo IQS if your institution requires a vendor-neutral AI solution to enhance and standardize ultrasound image analysis across existing cardiology and radiology workflows, both at the bedside and retrospectively on PACS. This tool is ideal for improving diagnostic confidence and efficiency through automated global and segmental cardiac function evaluation.

View LVivo IQS →

Choose Lung AI if…

Choose Lung AI if your clinical setting demands a highly portable, integrated handheld ultrasound device with on-device AI for rapid, point-of-care diagnostics, particularly for lung pathologies like pleural effusion and consolidation. This solution is best suited for emergency medicine, pulmonology, or situations requiring immediate, guided image capture and AI-powered insights without relying on external network connectivity.

View Lung AI →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	LVivo IQS	Lung AI
Deployment	As an integrated part of an ultrasound and information technology (IT) system.	Cloud-based, integrated with existing platforms (e.g., RapidAI), and potentially on-premise.
FDA Status	Yes AI-estimated	Cleared AI-estimated
HIPAA	Unknown	Yes AI-estimated

Head-to-Head

AI-generated assessment across six dimensions based on each tool's documented features and compliance posture. Grounded in public data — not a substitute for hands-on evaluation.

Usability

Lung AI

Tool B (Exo Iris with Lung AI) emphasizes ease of use for novice users and all skill levels, with features like a smartphone-like interface, guided image capture, and the integrated Exo U for POCUS education and training. This comprehensive approach aims to make advanced ultrasound highly accessible and user-friendly for a broader range of caregivers.

Clinical Value

LVivo IQS

Tool A (LVivo IQS) offers more detailed and quantitative cardiac function evaluation, including global and segmental left ventricle function (ejection fraction, strain, wall motion) and right ventricular function. Its accuracy in assessing ejection fraction has been validated against cardiac MRI, providing a deeper level of diagnostic precision crucial for cardiology.

Pricing & Value

Lung AI

Tool B (Exo Iris with Lung AI) provides transparent pricing for its device, stating a starting price of $3,500 or $4,999 for the Iris Essential Package, which includes a mandatory annual subscription of $1,200 after the first year. This transparency allows potential buyers to better understand the total cost of ownership, unlike Tool A which only states 'contact for pricing'.

Enterprise Readiness

LVivo IQS

Tool A (LVivo IQS) explicitly highlights its vendor-neutral software solution and its ability to integrate seamlessly with existing healthcare IT PACS systems and servers, often running 'behind the scenes'. This approach suggests a less disruptive and more adaptable integration into diverse hospital and clinic environments.

Innovation

Lung AI

Tool B (Exo Iris with Lung AI) stands out for its pioneering handheld ultrasound platform, integrating high-performance imaging with on-device AI processing that operates without an internet connection. This form factor, combined with its patented pMUT-based technology, represents a significant innovation in making advanced ultrasound highly portable and accessible at the point of care.

Support & Docs

Lung AI

Tool B (Exo Iris with Lung AI) clearly outlines multiple support channels, including email, phone, ticket submission, and SMS, and explicitly provides user manuals and release notes. Additionally, it integrates an innovative AI-powered educational platform, Exo U, to assist users with POCUS learning and training.

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	LVivo IQS	Lung AI
Product Name	LVivo IQS	Lung AI
Company	DiA Imaging Analysis	Exo
Tagline	AI-powered ultrasound analysis solutions for smarter, faster, and more accessible image interpretation.	Handheld AI Ultrasound for Smarter Cardiac and Lung Scanning.
Primary AI Focus	Automated analysis of ultrasound images for global and segmental left ventricle (LV) function, right ventricular (RV) function, and bladder volume measurement.	AI-powered detection of pleural effusion, consolidation/atelectasis, and automated AI-based indicators for cardiac conditions.
Real-time Feedback	AI-powered real-time image quality feedback (LVivo IQS)	Real-time feedback and image quality monitoring (SweepAI)
Vendor Neutrality / Device Integration	Vendor-neutral software solution	On-device AI processing (operates without internet), integrated with Exo Iris handheld ultrasound device.

Videos

Demos, reviews, and walkthroughs featuring LVivo IQS and Lung AI.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What clinical validation data is available regarding the accuracy and sensitivity of each tool's AI algorithms for their respective diagnostic capabilities?

LVivo IQS's FDA clearance for its Image Quality Score (IQS) was based on a clinical study showing high agreement between its AI feedback and the ability to obtain clinically interpretable images, with 91% of images saved by point-of-care residents being interpretable by cardiologists. Lung AI's algorithms for pleural effusion and consolidation/atelectasis detection have shown high accuracy, with reported sensitivities of 0.967 and 0.968, and specificities of 0.912 and 0.945 respectively, in a multi-reader, multi-case study. Exo's Cardiac AI also shows excellent agreement with expert LVEF measurements with an Inter Class Correlation (ICC) score of 0.91.

Given their distinct feature sets, for which specific clinical scenarios or patient populations would each tool be most advantageous?

LVivo IQS is particularly advantageous for detailed cardiac function assessment, including global and segmental LV/RV function evaluation, and general ultrasound image analysis, making it suitable for cardiology, emergency medicine, and radiology. Lung AI, with its focus on AI-powered detection of pleural effusion, consolidation/atelectasis, and automated cardiac indicators on a handheld device, is well-suited for point-of-care ultrasound (POCUS) in emergency medicine, pulmonology, and cardiology, especially for rapid bedside insights.

How steep is the learning curve for physicians and sonographers to effectively utilize each tool, and what resources are provided to ensure a rapid time-to-value?

LVivo IQS aims to reduce variability and increase efficiency through automated analysis and real-time image quality feedback, which can simplify the learning process. Lung AI explicitly addresses the learning curve with 'Guided image capture for optimal scans' and 'Exo U (AI-powered POCUS education and training)', which includes short, instructional videos and real-time feedback to help users rapidly learn POCUS.

For a healthcare system considering a multi-site rollout, how do the vendor-neutral capabilities of LVivo IQS compare to the integrated hardware approach of Lung AI in terms of implementation and scalability?

LVivo IQS, being a vendor-neutral software solution deployable on existing ultrasound devices and PACS systems, offers flexibility for integration across diverse hardware in a multi-site environment. Lung AI's on-device integration with the Exo Iris handheld ultrasound device implies a more standardized hardware rollout, which could offer consistent performance but requires adoption of their specific platform and its associated workflow solutions for multi-facility support.

Can you provide information on the level of customer support offered, including technical assistance and clinical application support, and are there opportunities to connect with existing customer references?

The provided descriptions do not explicitly detail the specific levels of customer support, technical assistance, or clinical application support for either tool. However, DiA Imaging Analysis has customer testimonials and videos available, indicating a history of customer engagement. Exo provides a support center with email, phone, and ticket submission options.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform

AISAP Cardio vs Rapid Enterprise Platform

AngioWaveNet vs Rapid Enterprise Platform

CorVista System with PH Add-On vs Rapid Enterprise Platform

More matchups featuring LVivo IQS or Lung AI

Backers

Who funded each tool's parent company.